You are here

Award Data

For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Improving Data, Improving Care, Making it Count, Integration Toolkit for Eliminating Double Data Entry

    SBC: Hdox Bioinformatics Inc.            Topic: N/A

    Phase II goals will be to: 1. To develop a production version of an Integration toolkit (ITK) that can deployed at low cost to clinics using spina bifida EMR (to improve the efficiency of their participation in the NSBPR) 2. To pilot the ITK at selected SB-EMR clinics 3. To evaluate the impact of the production version of the ITK The ITK will be developed based on design principles & specifica ...

    SBIR Phase II 2014 Department of Health and Human Services
  2. Innate Defense Regulator Peptide as a Therapeutic for Acute Pneumonic Melioidosis

    SBC: Soligenix, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): This proposal describes development of an immunomodulatory peptide that targets the host defense system for treatment of acute pneumonic melioidosis. The disease is caused by Burkholderia pseudomallei (Bps), a non-spore-forming motile saprophytic bacterium that can be transmitted from the soil to humans by inhalation, through cuts in the skin and by ingestion. ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Increasing viability of lung organs for transplantation

    SBC: TRIM-EDICINE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): While organ transplantation is a vital last resort therapy to treat patients with end-organ failure of the lung there is a growing waiting list of patients who are eligible for transplants as the number of suitable donor organs fall far short of the demand for these lifesaving procedures. Improving the preservation of donated organs so that a greater percentage ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. TRAIL Upregulation by TIC10 Analogs


    Project Summary/Abstract TIC10 (ONC201) is a first-in-class antitumor agent and small molecule inducer of the TRAIL gene which was identified in a high-throughput small molecule library screen in the lab of our collaborator, Dr. Wafik El-Deiry at Penn State University and has been shown to have preclinical efficacy in several difficult-to-treat disease settings that include unmet clinical needs su ...

    SBIR Phase I 2014 Department of Health and Human Services
  5. Development of Novel Fast GPU Monte Carlo and Active Photonics Simulation Softwar

    SBC: SIMPHOTEK, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Photodynamic therapy (PDT) is used for treating a variety of medical conditions including cancer. Even after many years of PDT research and the large-scale use of PDT treatments by physicians, there are many aspects ofPDT, such as quantitative predictions for diffusive light propagation and the kinetics of the light-material interactions, that are not well unde ...

    SBIR Phase I 2014 Department of Health and Human Services
  6. SGX942 to Decrease Oral Mucositis After Chemoradiation for Head and Neck Cancer

    SBC: Soligenix, Inc            Topic: NIDCR

    DESCRIPTION (provided by applicant): Oral mucositis has a significant impact on patient quality of life and outcomes during cancer therapy as well as having a significant pharmacoeconomic cost. There are no currently approved drugs to treat oral mucositisin patients with non-hematological malignancies, including head and neck cancer (HNC). Soligenix is developing a new compound, SGX942, a modulat ...

    SBIR Phase I 2014 Department of Health and Human Services
  7. Calcaftor, a CFTR stabilizer for Cystic Fibrosis treatment

    SBC: Calista Therapeutics, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Calista Therapeutics has invented Calcaftor, a first-in-class peptide drug that can treat all Cystic Fibrosis (CF) patients. Calcaftor is validated in the gold standard pre-clinical model of CF using F508 -CFTR lung tissue harvested from CF transplant patients. Results from this model demonstrated a gt25 hour duration of action that enables once daily inhaled n ...

    SBIR Phase I 2014 Department of Health and Human Services
  8. Wearable Monitor for Recording the Activity of Brown Adipose Tissue

    SBC: MMTC, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Brown Adipose Tissues (BAT) are tissues that when activated become metabolically active and take calories from normal white fat and burn them. Safe methods for creating and activating (BAT) would therefore be of great value in fighting obesity, a leading preventable cause of death with increasing prevalence in adults and children and one of the most serious pub ...

    SBIR Phase I 2014 Department of Health and Human Services
  9. Point of Care Breath Test for Biomarkers of COPD


    DESCRIPTION (provided by applicant): The clinical problem: Chronic obstructive pulmonary disease (COPD) affects an estimated 16 million people in the USA, and it is projected to increase from the sixth to the third most common cause of death worldwide by 2020. COPD imposes a burden on patients by restricting their everyday activities (e.g. walking up stairs), as well as a financial burden on socie ...

    SBIR Phase I 2014 Department of Health and Human Services
  10. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury


    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, mental retardation, and epilepsy. Cerebral oxygen deprivation and/or reduced blood flow due to umbilical cord occlusion, prolonged labor, and/or intracranial hemorrhage produce an inflammatory respons ...

    SBIR Phase I 2014 Department of Health and Human Services
US Flag An Official Website of the United States Government